Baker Bros. Advisors’s Acrivon Therapeutics ACRV Stock Holding History

Baker Bros. Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22,809	Closed	-$55K	–	85
2025 Q4	$55K	Hold	22,809	–	–	﹤0.01%	85
2025 Q3	$41.3K	Hold	22,809	–	–	﹤0.01%	89
2025 Q2	$27.1K	Hold	22,809	–	–	﹤0.01%	87
2025 Q1	$46.3K	Sell	22,809 -30,076	-57%	-$162K	﹤0.01%	87
2024 Q4	$318K	Hold	52,885	–	–	﹤0.01%	92
2024 Q3	$370K	Hold	52,885	–	–	﹤0.01%	91
2024 Q2	$307K	Hold	52,885	–	–	﹤0.01%	92
2024 Q1	$378K	Buy	+52,885	New	+$245K	﹤0.01%	82

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baker Bros. Advisors's ACRV Position: Q1 2026 in Review

Baker Bros. Advisors sold out of Acrivon Therapeutics (ACRV) in Q1 2026, closing a stake of 22,809 shares — an estimated $55K sold.

Baker Bros. Advisors first reported a position in ACRV in Q1 2024 and held it in 8 quarters. The position peaked at $378K in Q1 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Baker Bros. Advisors reported no remaining Acrivon Therapeutics position as of Q1 2026 after selling out during the quarter.
Baker Bros. Advisors sold 22,809 Acrivon Therapeutics shares in Q1 2026, an estimated $55K.
Baker Bros. Advisors first reported a position in Acrivon Therapeutics in Q1 2024 and held it in 8 quarters.
Baker Bros. Advisors's Acrivon Therapeutics position peaked at $378K in Q1 2024.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.